ArticleScientific reports2025
Wild grown Portulaca oleracea as a novel magnetite based carrier with in vitro antioxidant and cytotoxicity potential.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Plant-Derived Nanocarriers for Drug Delivery: A Unified Framework Integrating Extracellular Vesicles, Engineered Phytocarriers, Hybrid Platforms, and Bioinspired Systems.Plants (Basel, Switzerland) · 2026Review
- Article
- Design and Evaluation of aPolymers · 2025Article
- Design and Evaluation of aPharmaceutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The latest research on nanotechnology through the new tailored scaffolds encompassed the therapeutic effects of natural compounds, and the unique properties of metallic nanoparticles offer new possibilities in emerging biomedical fields. Various strategies have been developed to address the limitations of existing therapeutic agents concerning specificity, vectorization, bioavailability, drug resistance, and adverse effects. In this study, the medicinal plant Portulaca oleracea L. and magnetite nanoparticles were used to develop an innovative target carrier system, designed to enhance the cytotoxic effect and overcome the main drawbacks (permeability and localization) of the phytoconstituents. The low-metabolite profile of Romanian wild-grown Portulaca oleracea L. exhibits a diverse range of hundred fifty-five compounds across various chemical categories (amino acids, peptides, fatty acids, flavonoids, alkaloids, terpenoids, phenolic acids, organic acids, esters, sterols, coumarins, nucleosides, lignans, and miscellaneous compounds). Morpho-structural and magnetic properties of the new phytocarrier were investigated using a variety of methods, including XRD, FTIR, Raman, SEM, DLS), and magnetic determinations. The MTT assay was conducted to evaluate in vitro the potential cytotoxicity on normal human dermal fibroblasts (NHDF), as well as on two tumoral cell lines: human osteosarcoma (HOS) and cervical cancer (HeLa). Results indicated that significant inhibition of both cancer cell lines' viability was exerted by the new phytocarrier compared to herbal extract. Furthermore, the results obtained for the total phenolic content and the antioxidant potential screening performed using the FRAP and DPPH assays were superior for the new carrier system. These findings suggest the potential biomedical applications of the developed carrier system and its promising implications for future research and development in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.